|
Neue Besen kehren gut! Neuer CEO bei Stemmcells StemCells, Inc. Names Martin McGlynn New President and Chief Executive Officer; Former Pharmadigm CEO to Lead Executive Management Team Effective January 15, 2001 SUNNYVALE, Calif.--(BUSINESS WIRE)--Jan. 4, 2001--StemCells, Inc. (Nasdaq: STEM) announced today that effective January 15th, Martin McGlynn will become President and CEO of the Company. McGlynn brings several decades of international experience in the Life Sciences industry to his position. Prior to joining StemCells, Inc., he was President and CEO of Pharmadigm, Inc., a privately held company in Salt Lake City, Utah, which is engaged in research and development in the fields of inflammation and genetic immunization. During his time at Pharmadigm, McGlynn took the company through four rounds of financing, raising in excess of $50 million in private and venture capital. Mr. McGlynn`s prior experience includes President of Anaquest Inc., the Pharmaceutical Products Division of BOC Health Care and Vice President, Abbott International and President and General Manager of Abbott Canada Ltd. "We are extremely pleased that Martin is joining us," said John Schwartz, Chairman of the Board of Directors of StemCells, Inc. "We believe his experience and leadership skills make him ideal for StemCells at this point. We are also grateful to George Dunbar for the leadership he has provided the Company as it turned its focus to its core business of stem cell technology and for his continued involvement with the Company during our search for a new CEO." Mr. Dunbar has been Acting President and CEO of StemCells since February 2000. Mr. McGlynn is a native of Dublin, Ireland and began his Life Sciences career at Becton Dickinson Ireland, Ltd. He holds a Bachelor of Commerce from University College Dublin, and diplomas in Industrial Engineering and Production Planning from the Irish Institute of Industrial Engineering and the University of Birmingham, respectively. StemCells Inc. is a company engaged in the use of stem cell technology in the treatment of diseases characterized by damage to, or degeneration of, the central nervous system (CNS), liver, pancreas and other tissue. Statements in this press release other than statements of historical facts constitute forward looking statements regarding, among other things, the future business operations of StemCells, Inc., or of StemCells California, Inc., its wholly-owned subsidiary (collectively, "the Company"). The Company`s actual results may vary materially from those contemplated in the forward looking statements due to risks and uncertainties to which the Company is subject, including uncertainties regarding the Company`s ability to obtain the capital resources needed to conduct the research, preclinical development and clinical trials required to develop products and obtain regulatory approvals; the fact that the Company`s stem cell technology is at the pre-clinical stage and has not yet led to the development of any proposed product; the risk that any products that may be generated in the future in the Company`s stem cell programs may not prove clinically safe or effective or may cause tumors or other adverse side effects; the uncertainty whether the Company will achieve revenues from product sales or become profitable; and other risks and uncertainties described in Exhibit 99 to the Company`s Annual Report on Form 10-K entitled "Cautionary Factors Relevant to Forward Looking Statements." CONTACT: StemCells Inc. Ann Tsukamoto, Vice President, Scientific Operations 408/731-8670 or Susan E. Atkins & Associates Anette Breindl, 858/860-0266 Copyright 2001, Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire`s members, who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission. Home | About Nasdaq | Feedback | Help & Reference Equity & Index Options | Site Map, Index, Tour, Search Mr. Mc.Glynn scheint seinen Job gut zu machen! Scheint reichlich Erfahrung bei anderen Bio`s gesammelt zu haben. Vielleicht hilft das dem arg gebeutelten Kurs auf die Sprünge. Aber wichtig ist bei solchen Werten natürlich dranzubleiben! Gruß LM7 |
|
| aus der Diskussion: | Stemcells, Was haltet Ihr davon |
| Autor (Datum des Eintrages): | LMeister7 (04.01.01 12:52:43) |
| Beitrag: | 10 von 29 (ID:2627961) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |